


**LIFECARE**

# Quarterly Report

## Q3 2023



# Contents

Contents ..... 2

CEO’s Statement..... 3

Trigger event overview ..... 5

Market insight..... 6

Financials - Summary ..... 8

Progress – Trials and Operations .....15

Financial calendar .....16

Share capital increase history.....16

Shareholders as of 10.11.2023..... 17

Disclaimer..... 18

Contact .....19

About Lifecare.....19

# CEO's Statement

## QUALITY CONFIRMATIONS AHEAD OF PREPARATIONS FOR MARKET LAUNCH

During 2023, Lifecare's technology has been tested several rounds through study and experiments. According to our objectives, the miniaturized sensor, Sencell, must have at least as good a sensitivity as the competitors. This was initially confirmed with the MARD study in Q2. The operating time, on the other hand, must be in a class of its own compared to other devices in the market. Therefore, it has been satisfactory to have documented the sensor's operational time in a separate experiment which was completed in Q3. We are reaching more and more milestones, and the organization has also used the period wisely with a view to further certifications to achieve the necessary quality and standard. Step by step, we carry out what is required to prepare for the market launch next year.

## LONGEVITY – ANOTHER IMPORTANT BRICK / ANOTHER IMPORTANT PIECE OF THE PUZZLE

Lifecare has shown major progress in our plan to bring the smallest Continuous Glucose Monitor (CGM) system to the market. Testing in live tissue, continuous improvement of our Quality Management System and set up of manufacturing capabilities form the three main pillars in our market-oriented development.

At the start of Q3, we were also satisfied that we could announce the conclusions from the longevity experiment. The prototype sensors had reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This confirms both that our technology has a superior operational longevity compared to existing needle based CGM sensors, as well as an encouraging stability of the chemistry used in the in the sensor. This experiment validates the potential of Sencell to provide long-term and accurate glucose monitoring for people with diabetes, while reducing the need for frequent sensor replacements.

All these necessary steps are important preparations for production and the whole Lifecare organization focuses on quality measures to provide our long-term and accurate Continuous Glucose Monitoring system for people with diabetes. We are now very much looking forward to soon start testing the technology in dogs for up to 90 days through the upcoming study LFC-SEN-002.

## READY FOR ISO 13485

In accordance with the trigger events, as presented at the semi-annual report, we have reported in Q3 that Lifecare Laboratory (Mainz, Germany) was considered ready for ISO 13485 audit. We have also received confirmation that ISO 13485 audit at Lifecare Laboratory will be carried out in the middle of November 2023. ISO 13485 is specific to medical devices and covers the entire life cycle of a device, from design and development to production, installation, and servicing. Focus on Quality Management with regulatory compliance is essential for our operations to succeed with our core mission to introduce an implantable device for medical use to the market.

## PLACING ORDER FOR AUTOMATED PRODUCTION

The launch of an automated production line by end of Q2 2024 is set as a major Lifecare milestone. To accomplish this, the company has decided on the preferred partner and supplier of essential production machines and concluded to buy customized Scanning Electron Microscopes from Carl Zeiss IQS Deutschland GmbH (Zeiss) as the optimal cornerstone equipment for our automated production. The purchase order for an adopted software to Zeiss was placed in October. Following the delivery, the Lifecare NanoBioSensors team in Reutlingen, Germany, will further customize the software to initiate automated production of Lifecare Sencell.

## REPORTING TO SANOFI

Lifecare is engaged with Sanofi in a Product Development Agreement related to Sencell Continuous Glucose Monitoring system. Under the terms of the agreement, Sanofi has committed to provide funding contributions, supporting the further development of Lifecare's technology. In return, Lifecare has granted Sanofi a right of first refusal to negotiate, allowing them the first right to

negotiate an exclusive global license agreement for Lifecare's Sencell technology. In September we were pleased to announce that we submitted a phase-end report in line with the agreement. This event triggers the release of development funding from Sanofi while the Product Development Agreement continues. A couple of weeks into Q4 we finalized an additional phase end report under the Product Development Program and announced this accordingly.

### UPCOMING STUDY LFC-SEN-002

Last week we were pleased to receive approval to start LFC-SEN-002 from The Norwegian Food Safety Authority (NFSA). This study aims to investigate and document our technology longevity (in-vivo) and biocompatibility in-vivo. On the basis of both ethical and commercial considerations we have decided to proceed with LFC-SEN-002 as a study in dogs. The study will be carried out in collaboration with The Norwegian University of Life Sciences (NMBU) located at Ås, Norway.

The approval means that Lifecare can start working on the second study only six months after finalizing the successful Sencell clinical study: LFC-SEN-001. NFSA considers that the purpose of the experiment and the use of animals are satisfactorily described in the application and that the necessary requirements in the Laboratory Animal Regulations are met.

### PRIVATE PLACEMENT

In October Lifecare raised NOK 42.5 million in gross proceeds through a Private Placement of 17 million new shares in the Company, at a price per share of NOK 2.50.

The general investment climate has been under continuous pressure, and investors are in general acting very cautiously. On this background we were extra pleased to close this transaction with a reasonable discount of 15% for the participating investors. We have now secured the funds, we need to continue the targeted transformation of Lifecare into the industrial and commercial phase.

### VALUATION REPORT

Another important and noteworthy event that has been published in recent weeks is the new valuation report of the Sencell technology (CGM) for diabetes. Commissioned by Lifecare, the life science technology valuation-company Xplico carried out an in-depth value review of our technology. In this valuation, Xplico has taken into consideration various factors like development and market assumptions, comparable CGM technologies and concluded a valuation outcome.

The report provides an assessment of net present values of Lifecare's technology, assessments regarding the probability of success in the markets we have targeted. In addition, the report shows market share and anticipated annual treatment price at launch. For the very first time, the spin-off venture towards the veterinary market has also received a separate review. The valuations of the technology in the markets for both humans and pets confirm the possibilities of Lifecare's technology.

### OUTLOOK SUMMARY

- Q4 ISO 13485 audit
- Q4 Place order for Scanning Electron Microscope for production.
- Q4 Place order for customized nanofluidic production units (filling and sealing).
- Q4 Preparing for LFC-SEN-002 and LFC-SEN-003
- Q1 Start LFC-SEN-002
- Q1 Submit study protocols (LFC-SEN-003) for regulatory approval.
- Q1 ISO 13485 certification



Joacim Holter  
CEO

# Trigger event overview



# Market insight

## MARKET OPPORTUNITY AND IMPACT OF GLP-1

GLP-1 drugs is a class of drugs that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. The GLP-1 class of drugs has been indicated for use in type 2 diabetes since 2005. GLP-1 therapy has been increasingly relevant since then and especially in the last three years. Ongoing adoption of the GLP-1 class of drugs in diabetes and recent news surrounding the expansion of use of GLP-1 in obesity have led to several questions regarding the impact on the insulin therapy and CGM market.

This autumn, both Abbott, Dexcom and Insulet have published analyzes that illustrate some preliminary trends related to the topic and how this might affect product sales and their market prospects.

Lifecare has not carried out its own analyzes regarding the increasing use of GLP-1 therapy and how this may possibly affect the demand for our Sencell after-market launch. We follow the debate and the analyzes that are published within the diabetes community and in the industry.

Current analyzes from Abbott conclude that at the same time as the use of GLP-1 therapy has increased, the number of FreeStyle Libre users has continued to grow rapidly. At the same time Abbott has experienced that the number of FreeStyle Libre users who also use GLP-1 therapy has increased significantly over time. In addition to this, the CGM supplier indicates that the number of days the sensor is used is higher for those who also use the GLP-1 therapy.

## As the use of GLP-1 therapy has increased, the number of FreeStyle Libre users has continued to grow rapidly




Figure: Abbot FreeStyle Libre / GLP-1 Analysis, September 28<sup>th</sup>, 2023

A Dexcom investor presentation published September 2023 also concludes that across all segments of type 2 diabetes, CGM use increases with GLP-1 initiation. Dexcom explains the various aspects of the clinical drivers for CGM use with GLP-1. They claim it provides the patients insight and behavior modification, supports dose titration, helps enable durability of health outcomes and increasing access and simplicity (of CGM systems supports continued acceleration of CGM adoption across all T2D segments, including with GLP-1 use).




Figure: Dexcom Investor Presentation, September 2023

In a report from Insulet published November 2<sup>nd</sup>, 2023, they analyze the market opportunity and impact of GLP-1 in their end markets in type 1 and type 2 diabetes. The producer of insulin pumps conclude that Type 1 diabetes is a large underpenetrated market that is not expected to be impacted by GLP-1 therapy. Type 2 diabetes is a progressive disease that presents gradually, but leads inevitably to insulin therapy in advanced stages. Insulet also emphasizes that insulin and GLP-1s are often used in combination and GLP-1s make insulin therapy more efficacious.

The insulin market in type 2 is large and underpenetrated. It is fed by very large populations that progress inevitably from many factors (e.g., obesity), through pre-diabetes, into type 2 diabetes, and eventually onto insulin therapy. In the end Insulet’s report points out that the market for insulin therapy will remain large and underpenetrated for the foreseeable future.

# Financials - Summary

## PREPARATION AND DEVELOPMENT

The Q3 financials are characterized by Lifecare's continued investments to reach the goal of launching a product on the market in 2024. The company's costs are stable from quarter to quarter while the revenues have slightly increased compared to the previous quarter.

Lifecare's operational priorities towards automated production and market launch reduce the capacity to provide services to third-party customers, and consequently revenues have decreased from 6,75 MNOK in Q3 2022 to 2,57 MNOK in Q3 2023. As the operational focus will continue, we do not foresee significant increase in revenues in the short term.


The operational priorities naturally lead to increased investment to product development and production preparations. At the same time, decrease in revenue compared to last year affect the operating result concluded at -20,57 MNOK YTD 2023 compared to -6,92 MNOK YTD 2022.

The Group cash position and equity as of Q3 2023 are strengthened compared to Q3 2022, without taking the capital increase finalized October 20<sup>th</sup>, 2023, into account.

## KEY FINANCIAL

Financial statement 30 September 2023 unaudited (MNOK),	Q3 2023	Q3 2022	YTD 2023	YTD 2022
Revenue	2,57	6,75	6,41	15,43
Salaries and personnel costs	-4,82	-2,35	-13,09	-6,50
Other operating costs	-4,41	-4,82	-13,89	-15,84
Sum operating result	-6,66	-0,42	-20,57	-6,92
Net finance	-0,08	-0,05	-0,44	0,08
<b>Sum</b>	<b>-6,74</b>	<b>-0,47</b>	<b>-21,00</b>	<b>-6,84</b>
Equity	33,29	19,10	33,29	19,10
<b>Total Assets</b>	<b>45,81</b>	<b>37,76</b>	<b>45,81</b>	<b>37,76</b>
Earning per share	-0,060	-0,007	-0,184	-0,076





## CONSOLIDATED FIGURES, LIFECARE GROUP (UNAUDITED FIGURES)

Q3 IFRS 2023	Q3 IFRS 2022	NOK	YTD IFRS 2023	YTD IFRS 2022
2 567 585	6 747 361	OPERATING INCOME	6 407 878	15 425 981
-4 818 841	-2 350 698	SALARIES AND OTHER PERSONNELL EXP.	-13 087 077	-6 504 293
-346 365	-835 764	DEPRECIATION AND AMORTIZATION COSTS	-1 344 271	-1 443 235
-257 312	-160 057	AMORTIZATION ROA	-757 165	-522 602
-3 803 472	-3 825 435	OTHER OPERATING COSTS	-11 785 931	-13 874 746
-9 225 989	-7 171 954	OPERATING EXPENSES	-26 974 444	-22 344 875
-6 658 404	-424 593	OPERATING RESULT	-20 566 566	-6 918 894
42 469	35 283	FINANCE INCOME	101 895	255 429
-122 867	-83 852	FINANCE COSTS	-537 208	-173 483
-80 398	-48 569	NET FINANCIAL ITEMS	-435 313	81 946
-6 738 802	-473 162	ORDINARY RESULT BEFORE TAXES	-21 001 880	-6 836 949
-290 019	-216 661	TAXES	-722 085	-713 014
-7 028 821	-689 823	ORDINARY RESULT	-21 723 964	-7 549 962
-0,060	-0,007	Earnings per share (basic)	-0,184	-0,076

## BALANCE SHEET, LIFECARE GROUP (UNAUDITED FIGURES)

Q3	Q3	NOK	YTD	YTD	
IFRS	IFRS		IFRS	IFRS	
5 520 690	6 719 361	LICENCES AND PATENTS	5 520 690	6 719 361	
7 330 832	6 551 916	GOODWILL	7 330 832	6 551 916	
12 851 522	13 271 277	INTANGIBLE ASSETS	2	12 851 522	13 271 277
3 282 977	1 409 622	MACHINERY AND EQUIPMENT	3 282 977	1 409 622	
-	-	INVESTMENTS IN AFFILIATED COMPANIES	4	-	-
3 096 855	4 237 706	RIGHT-OF-USE ASSET	3 096 855	4 237 706	
6 379 832	5 647 328	TOTAL FIXED ASSETS	2	6 379 832	5 647 328
1 499 755	1 445 486	RECEIVABLES	1 499 755	1 445 486	
5 197 260	6 002 369	OTHER CURRENT FINANCIAL ASSETS	5 197 260	6 002 369	
19 880 443	11 390 420	CASH AND CASH EQUIVALENTS	19 880 443	11 390 420	
26 577 459	18 838 276	TOTAL CURRENT ASSETS	26 577 459	18 838 276	
<b>45 808 813</b>	<b>37 756 880</b>	<b>TOTAL ASSETS</b>	<b>45 808 813</b>	<b>37 756 880</b>	
87 453 295	42 454 581	PAID UP EQUITY	87 453 295	42 454 581	
-54 161 858	-23 353 968	RETAINED EQUITY	-54 161 858	-23 353 968	
33 291 436	19 100 613	TOTAL EQUITY	3,5	33 291 436	19 100 613
1 640 914	1 435 800	DEFERRED TAX	1 640 914	1 435 800	
5 942 898	1 829 134	LONG-TERM NON INT.BEARING DEBT	5 942 898	1 829 134	
2 408 048	3 333 342	FINANCIAL LEASE LONG TERM	2 408 048	3 333 342	
9 991 860	6 598 276	TOTAL LONG-TERM DEBT	9 991 860	6 598 276	
602 896	3 287 810	ACCOUNTS PAYABLE	602 896	3 287 810	
248 410	7 031 615	GOVERNMENT TAXES	248 410	7 031 615	
1 674 211	1 738 566	OTHER CURRENT LIABILITIES	1 674 211	1 738 566	
2 525 517	12 057 991	TOTAL CURRENT LIABILITIES	2 525 517	12 057 991	
<b>45 808 813</b>	<b>37 756 880</b>	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>45 808 813</b>	<b>37 756 880</b>	

## CASH FLOW, LIFECARE GROUP

NOK	YTD 2023	YTD 2022
	(Unaudited)	(Unaudited)
<b>CASH FLOW FROM OPERATING ACTIVITIES:</b>		
EBIT	-21 001 880	-6 836 949
TAXES PAID	-	-
DEPRECIATION	1 344 271	1 443 235
CHANGE IN RECEIVABLES	-178 121	-1 306 790
CHANGE IN ACCOUNTS PAYABLE	-1 024 740	1 315 385
CHANGES IN OTHER ACCRUED INCOME AND EXPENDITURE	-3 028 624	-1 392 154
CURRENCY CONVERSION DIFFERENCES		-
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>-23 889 094</b>	<b>-6 777 273</b>
<b>CASH FLOW FROM INVESTMENT ACTIVITIES:</b>		
NEW NON-CURRENT ASSETS	-1 637 716	-5 617 588
INVESTMENTS IN FIXED FINANCIAL ASSETS	610 946	-4 444 833
NEW SHORT-TERM RECEIVABLES	620 123	-3 713 890
<i>NET CASH FLOW FROM INVESTMENT ACTIVITIES</i>	<i>-406 647</i>	<i>-13 776 311</i>
<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
NEW LONG-TERM DEBT	3 229 819	3 901 300
NEW SHORT TERM DEBT	-6 684 038	7 000 841
PAID-IN EQUITY		
DIVIDEND	-	
<i>NET CASH FLOW FROM FINANCING ACTIVITIES</i>	<i>-3 454 220</i>	<i>10 902 141</i>
<b>NET CASH FLOW TOTAL</b>	<b>-27 749 961</b>	<b>-9 651 442</b>
<b>CASH AT BEGINNING OF THE PERIOD</b>	<b>47 630 404</b>	<b>21 041 862</b>
<b>CASH AT THE END OF THE PERIOD</b>	<b>19 880 443</b>	<b>11 390 420</b>

## NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENT

### 1. Organization and basis of preparation

#### Organization:

Lifecare AS ("Company") is a Norwegian based clinical stage medical sensor company with subsidiaries in Bergen (Norway), Mainz, Reutlingen (Germany) and Bath (UK) ("Lifecare Group"). Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. The Company's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.

Lifecare AS is listed on the Oslo Stock Exchange, Euronext Growth, with ticker LIFE.

#### Basis of presentation:

1st of January 2023 is the company's implementation date for conversion to International Financial Reporting Standards (IFRS) from NGAAP. More information on the opening balance as of January 1st, 2022, comparative balance as of 31 December 2022, and the effects of the transition to IFRS would be found in the first quarterly report of 2023.

These condensed interim financial statements prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB) and as adopted by the European Union (EU). For a complete set of financial statements, these condensed interim financial statements should be read in conjunction with the annual statement of 2022 (NGAAP).

The condensed interim financial statements are unaudited. The audit will be carried out in connection with the 2023 yearend closing.

#### Fair Value:

The condensed interim financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the dates and interim periods presented. Interim period results are not necessarily indicative of results of operations or cash flows for an annual period.

#### Use of estimates:

The preparation of financial statements in conformity with simplified IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis, considering current and expected future market conditions.

## 2. Intangible assets, plant, equipment, and ROA

	Patents and licenses	Goodwill	Tangible assets	RIGHT OF USE ASSETS (IFRS 16)	Total
Cost 01.01.23	7 812 443	7 330 832	3 581 542	4 044 978	22 769 795
Purchased fixed assets					
Asset consolidation					
Cost 30.09.23	7 812 443	7 330 832	3 581 542	4 044 978	22 769 792
Acc. depreciation	2 291 753		668 302	948 123	3 222 074
Book value 30.09.23	5 520 690	7 330 832	3 282 977	3 096 855	19 231 354
Depreciation 2023	475 669		522 238	757 165	1 755 072

Lifecare Group has recognized two of its office facilities as a leasing contract according to IFRS 16. Lease liabilities according to IFRS 16 is measured as the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate.

Office rent due within 12 months are classified as short-term.

The company elected to use the recognition exemptions for lease contracts that, at the commencement date, have a lease term of 12 months or less and do not contain a purchase option ('short-term leases') and lease contracts for which the underlying asset is of low value ('low-value assets')

## 3. Equity

Equity Group	Share capital	Share premium reserve	Retained equity	Total equity
01.01.2023	47 146 297	40 306 997	-32 203 203	55 250 091
Effect of transition to IFRS			688 729	688 729
Share capital increase				
Currency conversion differences			-923 420	-923 420
Result 2023			-21 723 964	-21 723 964
<b>Book value 30.09.2023</b>	<b>47 146 297</b>	<b>40 306 997</b>	<b>-53 271 159</b>	<b>33 291 436</b>

## 4. Subsidiaries

Lifecare owns 100% of Lifecare Nanobiosensors GmbH. The subsidiary's result for the first three quarters of 2023 was 0,214 MNOK and the equity was 0,450 MNOK. The company has been consolidated into the consolidated accounts with effect from 01.07.2021.

Lifecare owns 100% of Lifecare Laboratory GmbH. The subsidiary's result for the first three quarters of 2023 was NOK -0,361 MNOK and the equity was 4,6 MNOK. The company is consolidated into the consolidated accounts with effect from 01.02.2022.

Lifecare owns 100% in Lifecare Chemistry Ltd. The subsidiary's result for the first three quarters of 2023 was -0,060 MNOK and the equity was 0,333 MNOK. The company was established 03.11.22 and was consolidated into the consolidated accounts with effect from 01.12.2022.

Lifecare owns 80% of the shares in Lifecare Veterinary AS. The company was consolidated into the Group accounts with effect from 01.06.2023.

## 5. Shareholders

The share capital of Lifecare as of 30.06.23 consists of 117,865,742 ordinary shares of NOK 0.40, in total NOK 47,146,297. The main shareholders per 30.09.23 was:

Shareholder	Shares	Stake
Teigland Eiendom As	24 691 829	20,95 %
Lacal As	18 187 712	15,43 %
Verdipapirfondet Nordea Avkastning	8 770 413	7,44 %
Spit Air As	3 087 735	2,62 %
Sandquist Patricia Rodrigues Da Costa	2 863 000	2,43 %
Westhawk As	2 555 164	2,17 %
Nordnet Livsforsikring As	2 301 028	1,95 %
Deutsche Bank Aktiengesellschaft	2 120 718	1,80 %
Einarsen Even Harald	2 100 000	1,78 %
Bnp Paribas	1 812 600	1,54 %
Nexus Marketing	1 732 024	1,47 %
Andreassen Kurt Normann	1 332 872	1,13 %
Cimter As	1 331 355	1,13 %
Other (under 1% share)	44 979 292	38,16 %
Total shareholders	117 865 742	100,00 %

Primary insiders and related holdings	2023	2022	Stake 2023
Hanibal Invest AS (primary insider Hans Hekland)	200 000	200 000	0,17 %
Cimter AS (primary insider Joacim Holter)	1 331 355	1 331 355	1,13 %
Joacim Holter	317 997	317 997	0,27 %
Islay Venture GmbH (primary insider Andreas Pfützner)	2 620 499	2 620 499	2,22 %
Total shareholders	4 469 851	4 469 851	3,79 %

The CEO directly/indirectly owns 1.4% of the shares in the company.

The CSO indirectly owns 2.2 % of the shares in the company.

# Progress – Trials and Operations

## Status

- LFC-SEN-001 was finalized in 1H 2023. Data from the study confirm a solid clinical accuracy of our technology (Sencell). The mean average of absolute error (MARD) between Sencell and matched relative reference values in the study was 9,6%, meaning that our sensor technology is in line with the gold standard for glucose monitoring (range 5%-10%).
- The prototype sensors had reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This confirms both that our technology has a superior operational longevity compared to existing needle based CGM sensors.

## Recent progress

- Sensors used in LFC-SEN-001 have been explanted from the test persons and transferred to in-vitro testing. The extended experiment confirms very encouraging sensor longevity, functionality of 24 weeks and was announced in July 2023. Oppdater
- We have received approval to start LFC-SEN-002 from The Norwegian Food Safety Authority (NFSA). This study aims to investigate and document our technology longevity (in-vivo) and biocompatibility in-vivo. The study will be carried out in collaboration with The Norwegian University of Life Sciences (NMBU) located at Ås, Norway.
- Delays from sub-supplier responsible for the wireless communication from Lifecare's sensor to the read-out-device will affect LFC-SEN-002.

## Prospects

- The manufacturing preparations have been initiated according to plan. Alongside a strictly detailed internal operational focus, the upcoming main events for manufacturing preparations is to place orders for the production equipment essential for automatization, in Q4 2023. Already ongoing customization of software and equipment will continue throughout Q4 2023 and Q1 2024.
- The continuous development and improvement of Lifecare's Quality Management System (QMS) continues and the QMS team are ready for the important ISO 13485 audit in the course of November 2023. Subject to the audit conclusion, the ISO13485 certification can be expected in the first part of Q1 2024.
- LFC-SEN-002 will start in Q1 2024. This is a postponement compared to our previously communicated roadmap; however, we do not expect that this occurrence will affect the planned progress towards automated production and market readiness by end of Q2 2024. The postponement is a result of delay in services from one of our sub-suppliers on wireless radiocommunication. Currently we have engaged three individual service providers to ensure delivery of radiocommunication solutions in accordance with Lifecare specifications in Q1 2024, This will ensure that manage to initiate LFC-SEN-002 in accordance with this adjustment.
- Study protocols and additional preparations for LFC-SEN-003 will be initiated in Q4 2023. Submission for regulatory approval for LFC-SEN-003 is planned for Q1 2024.
- Timelines are depending on regulatory approvals and, internal and external manufacturing capabilities.

# Financial calendar

## FINANCIAL YEAR 2023:

27.02.2024 Q4 Report

09.04.2024 Annual Report

## FINANCIAL YEAR 2024:

30.04.2024 Annual General Meeting

08.05.2024 Q1 Report

27.08.2024 Semi-annual Report 1H

13.11.2024 Q1 Report

# Share capital increase history.

## Historic overview capital increase

	2018	2021	2022	2023
<b>Total</b>	33 MNOK	26,3 MNOK	45 MNOK	42,5 MNOK
<b>Share price</b>	1,33 NOK	1,70 NOK	2,50 NOK	2,50 NOK



# Shareholders as of 10.11.2023

	No.of shares	%
TEIGLAND EIENDOM AS	24 691 829	18,31 %
LACAL AS	21 387 712	15,86 %
VERDIPAPIRFONDET NORDEA AVKASTNING	8 770 413	6,50 %
TJELTA AS	8 000 000	5,93 %
SPIT AIR AS	3 087 735	2,29 %
SANDQUIST PATRICIA RODRIGUES DA COSTA	2 886 400	2,14 %
NORDNET LIVSFORSIKRING AS	2 780 998	2,06 %
LT FINANS AS	2 500 000	1,85 %
EINARSEN EVEN HARALD	2 400 000	1,78 %
DEUTSCHE BANK AKTIENGESELLSCHAFT	2 120 718	1,57 %
WESTHAWK AS	2 054 182	1,52 %
BNP PARIBAS	1 812 600	1,34 %
NEXUS MARKETING	1 752 024	1,30 %
ANDREASSEN KURT NORMANN	1 652 872	1,23 %
MAX INVEST AS	1 445 000	1,07 %
CIMTER AS	1 331 355	0,99 %
CLEARSTREAM BANKING S.A.	1 087 779	0,81 %
HEJMA AS	1 000 000	0,74 %
NORDNET BANK AB	977 896	0,73 %
PROBE AS	905 012	0,67 %
Sum	92 644 525	69 %
Remaining shareholders (2000+)	42 221 217	31 %
Shareholders	134 865 742	100 %

# Disclaimer

The information in this presentation has been prepared by Lifecare (the "Company"). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the following limitations and provisions:

This presentation has been prepared based on information available as of the date hereof. No representation or warranty (expressor implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company, or any advisor or any such persons' officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. The Company is in its early stages of development and is considered to be a venture company. Venture companies in general entail a high degree of risk. It is highly recommended that potential investors seek further advice of risks associated with venture investments in general, and in particular specific risks for the Company. The information herein is subject to change, completion, supplements or amendments without notice. By relying on this presentation, you accept the risk that the presentation does not cover matters that could have been disclosed, have a more comprehensive investigation been carried out.

The presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof and may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. It should be understood that subsequent developments may affect the information contained in this document, which neither the Company nor its advisors are under an obligation to update, revise or affirm.

This complete presentation is for informational purposes only and does not constitute an offer to sell shares in of the company. This presentation is not a prospectus, disclosure document or offering document and does not purport to be complete.

This presentation has not been reviewed or approved by any regulatory authority or stock exchange. The (re)distribution of this presentation and/or any prospectus or other documentation into jurisdictions other than Norway may be restricted by law. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to acquire any securities offered by any person in any jurisdiction in which such an offer or solicitation is unlawful. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such restrictions.

The presentation and any purported liability in connection with it is subject to Norwegian law and is subject to the exclusive jurisdiction of the Norwegian courts.

# Contact

## CONTACT

Name Joacim Holter

Title CEO

Mobil +47 40059040

e-mail [joacim.holter@lifecare.no](mailto:joacim.holter@lifecare.no)

Name Asle Steiestøl Wingsternes

Title Head of Comm. & Public affairs

Mobil +47 41 61 42 52

e-mail [asle.wingsternes@lifecare.no](mailto:asle.wingsternes@lifecare.no)

## VISITING ADDRESS

Ytrebygdsvegen 215

5258 Blomsterdalen

## LINKEDIN

<https://www.linkedin.com/company/lifecare-as/>

# About Lifecare

Lifecare develops biosensor-technology for medical use. The biosensors are miniaturized to the size of a grain of rice due to the company's capacity to manipulate pressure-sensing elements in the nanoscale.

Our proprietary technologies have the potential to improve medical products by adding sensing functionalities to devices in all medical indications.

We have a particular focus on diabetes and are dedicated to helping the more than 500 million people living with diabetes.